Individualizing treatment duration in hepatitis C virus genotype 2/3‐infected patients
- 12 October 2010
- journal article
- review article
- Published by Wiley in Liver International
- Vol. 31 (1) , 36-41
Abstract
The drugs currently licensed for the treatment of hepatitis C are Peg-Interferon (PEG-IFN) and ribavirin. In recent years, the recommendation to treat hepatitis C virus genotype 2- and 3-infected patients with a fixed 800 mg/day dose of ribavirin in combination with PEG-IFN and for just 24 weeks has been challenged by the concept of tailoring the length of therapy according to on-treatment viral response. Therefore, the objective of the present review was to highlight the different designs of the studies on short treatment duration and the role of wk4-R as a predictor of sustained virological response after an abbreviated course of treatment. The secondary aim was to verify whether we had enough evidence to support the implementation of a short treatment course in subsets of patients with genotype 2 and 3 infection. We will also focus on how drug dosing may have influenced the outcome of treatment. To clarify reasons for discrepant results in the studies so far published, the recently discovered genetic variant near the interleukin 28B gene will be presented and its predictive role will be discussed. Finally, we will face the debated issue of whether the subset of patients with genotype 2 or 3 requires an extended treatment duration.Keywords
This publication has 24 references indexed in Scilit:
- Replicated Association Between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and RibavirinGastroenterology, 2010
- Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis CNature Genetics, 2009
- IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapyNature Genetics, 2009
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature, 2009
- Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C InfectionNew England Journal of Medicine, 2009
- Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection #Hepatology, 2009
- Cost minimisation analysis of 12 or 24 weeks of peginterferon alfa-2b + ribavirin for hepatitis C virusJournal of Medical Economics, 2008
- A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis CGut, 2007
- Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of TreatmentGastroenterology, 2006
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirinJournal of Hepatology, 2005